ClinicalTrials.gg
Not yet recruitingNCT07310771Updated Dec 30, 2025

Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II

A Phase 2 interventional study of Sintilimab combined with chemotherapy and nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN), sponsored by Fujian Cancer Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Fujian Cancer Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing sintilimab in Squamous Cell Carcinoma of Head and Neck — 7 open to participants now, 8 under way, 2 of them phase 3. sintilimab · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
11th of 11
23 · median 51
Started
2026
with 3 others
Phase 2
9 of 11
5 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
Fujian Cancer Hospital

Among the 11 studies testing sintilimab in Squamous Cell Carcinoma of Head and Neck, this one is the 11th largest by planned enrollment, is one of 4 that started in 2026, is one of 9 in phase 2, and was the 9th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

7 of the 11 studies testing sintilimab in Squamous Cell Carcinoma of Head and Neck are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing sintilimab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

Although multiple immune-checkpoint inhibitors (ICIs) have demonstrated efficacy in recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M-SCCHN), outcomes in the locally advanced (LA-SCCHN) setting remain suboptimal, and treatment continues to pose a major therapeutic challenge. Incremental improvements in efficacy are still required, necessitating the development of more effective regimens. Whether combining an ICI with chemotherapy and nimotuzumab can confer additional clinical benefit in LA-SCCHN remains to be determined. Against this backdrop, we designed a single-arm, phase II, single-centre clinical trial to evaluate the efficacy and safety of sintilimab plus chemotherapy and nimotuzumab for patients with LA-SCCHN.

03

Conditions studied

  • Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written , with full understanding of and agreement to comply with study requirements and the visit schedule.
  2. Age 18-75 years (inclusive) at the time of informed consent; either sex.
  3. (ECOG) performance status 0 or 1.
  4. or cytologically confirmed stage III-IVB squamous cell carcinoma of the head and neck as assessed by the investigator.
  5. Documented EGFR-positive tumor.
  6. No prior systemic therapy for head and neck squamous cell carcinoma.
  7. At least one per v1.1.
  8. Estimated ≥ 12 weeks.
  9. Adequate bone-marrow and organ function.

Exclusion criteria

Exclusion Criteria:

  1. Known to any component of PD(L)-1 inhibitors, paclitaxel, or cisplatin.
  2. Prior or concurrent (except adequately treated basal-cell carcinoma, cervical carcinoma in situ, or papillary thyroid carcinoma disease-free for >5 years).
  3. Uncontrolled cardiac symptoms or cardiac disease.
  4. Previous therapy with , anti-PD-L1, or anti-CTLA-4 antibodies, or receipt of therapeutic cancer vaccines or within 4 weeks before first study-dose administration.
  5. Failure to recover to ≤ Grade 1 (per ) from prior anti-tumour therapy-except alopecia or residual neurotoxicity related to prior platinum-before first study dose.
  6. Severe infection (> CTCAE Grade 2) within 4 weeks before first study dose.
  7. Active disease or documented autoimmune-disease history requiring systemic therapy.
  8. History of immunodeficiency, including positive test, congenital or acquired immunodeficiency syndromes, or prior solid-organ or bone-marrow transplantation.
  9. History of interstitial lung disease or non-infectious pneumonitis.
  10. Evidence of active tuberculosis infection on history or CT imaging.
  11. Active (HBV DNA ≥ 500 IU/mL or ≥ 2,500 copies/mL).
  12. History of substance abuse, alcohol abuse, or drug addiction.
  13. Pregnant or lactating women.
  14. Any condition that, in the investigator's opinion, could necessitate premature withdrawal from the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (estimated)

Study arms

  • Experimental
    Sintilimab combined with chemotherapy and nimotuzumab for patients with LA-SCCHN

    Drug: Sintilimab combined with chemotherapy and nimotuzumab

Interventions

  • DrugSintilimab combined with chemotherapy and nimotuzumab

    Drug pages: SintilimabStudies of SintilimabSintilimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · NimotuzumabStudies of NimotuzumabNimotuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The study plans to enroll patients with locally advanced squamous cell carcinoma of the head and neck. After induction with sintilimab plus paclitaxel, cisplatin, and nimotuzumab, participants will receive concurrent chemoradiotherapy with nimotuzumab, followed by maintenance sintilimab monotherapy until disease progression, unacceptable toxicity, death, or withdrawal of consent.

06

What researchers measure

Primary outcomes

  1. Larynx-preservation rate at 3 months post-radiotherapy

    Time frame: 3 months

Secondary outcomes

  1. objective response rate

    Time frame: 24 months

  2. One-year progression-free survival (PFS) rates

    Time frame: 12 months

  3. Two-year progression-free survival (PFS) rates

    Time frame: 24 months

  4. One-year loco-regional relapse-free survival (LRFS) rates.

    Time frame: 12 months

  5. two-year loco-regional relapse-free survival (LRFS) rates.

    Time frame: 24 months

  6. One- year distant-metastasis-free survival (DMFS) rates.

    Time frame: 12 months

  7. two-year distant-metastasis-free survival (DMFS) rates

    Time frame: 24 months

  8. One-year larynx-preservation rates

    Time frame: 12 months

  9. AE/SAE

    Time frame: 42 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jul 2027, 18 months later.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 18 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartEst.
Jan 10, 2026
Primary completionEst.
Jul 10, 2027
CompletionEst.
Jul 10, 2029
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07310771
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Jan 10, 2026 (estimated)
Primary completion
Jul 10, 2027 (estimated)
Completion
Jul 10, 2029 (estimated)
Last update
Dec 30, 2025

Study contacts

Yun Xu
Contact
308466040@qq.com
+86 136 0088 3867

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sintilimab · Nimotuzumab

Start the discussion